On Feb. 10, 2021, RELIEF THERAPEUTICS announced the release of preliminary results from the phase 2b/3 trial of intravenously administered RLF-100ﾙ by its partner NeuroRx. The preliminary data suggested that the administration of intravenous RLF-100ﾙ could reduce the length of hospital stay among patients with respiratory failure due to critical COVID-19 compared to placebo plus maximal standard of care.